JAK Inhibitor Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$513M

Range: $272M - $743M

Total Deal Value

$2.7B

Range: $1.7B - $3.7B

Royalty Rate

13.5% - 22.5%

Tiered up to 26.5%

Dev Milestones

$432M

Range: $277M - $590M

Model Your Deal

Market Analysis

JAK Inhibitor therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 jak inhibitor asset in immunology & autoimmune is $513M, with total deal values reaching $2.7B. Development milestones average $432M, while regulatory milestones contribute $757M.

The immunology & autoimmune jak inhibitor landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for jak inhibitor immunology & autoimmune deals range from 13.5% to 22.5% at the base tier, with tiered escalation reaching 17.5%-26.5% on blockbuster sales. Commercial milestones averaging $973M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a jak inhibitor immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 jak inhibitor licensing deals in immunology & autoimmune average $513M in upfront payments, with a range of $272M to $743M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for jak inhibitor immunology & autoimmune transactions?

The median total deal value for Phase 2 jak inhibitor assets in immunology & autoimmune is $2.7B, ranging from $1.7B to $3.7B. This includes development milestones ($432M), regulatory milestones ($757M), and commercial milestones ($973M).

What royalty rates are standard for jak inhibitor deals in immunology & autoimmune?

Base royalty rates for jak inhibitor immunology & autoimmune transactions range from 13.5% to 22.5%, with tiered escalations reaching 17.5%-26.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in jak inhibitor immunology & autoimmune deals?

JAK Inhibitor immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($432M) make up the largest share, followed by commercial milestones ($973M) and regulatory milestones ($757M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

JAK Inhibitor Deal Benchmarks in Immunology & Autoimmune

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Immunology & Autoimmune

Monoclonal Antibody in Immunology & Autoimmune

JAK Inhibitor in Dermatology

JAK Inhibitor in Gastroenterology

Ready to Calculate Your Deal Terms?